Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
The resulting company, Aurobac Therapeutics SAS, will combine the best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure. The aspiration is to succeed in the fight against AMR, which is a major public health threat. Having routine surgery such as caesarean sections or hip replacements may become life threatening, and complications from common diseases such as diabetes and injuries or cuts will become harder to manage because of growing resistance to antibiotics in patients.
“The rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR – is indeed a looming global crisis,” said Michel Pairet, Head of Boehringer Ingelheim’s Innovation Unit and Member of the Board of Managing Directors. “Antibiotic resistance kills about 1.27 million people globally every year1 and it has been estimated that by 2050, as many as 10 million worldwide deaths could result from AMR2, making it potentially deadlier than cancer.”
Werner Lanthaler, CEO of Evotec added: “The grim prospect of a post-antibiotic era has many causes but only one solution: The development of new, targeted, and effective antimicrobial therapies. We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMérieux, to combine our complementary strengths. By leveraging Evotec’s multimodality approach to infectious diseases, we are confident that Aurobac will be able to generate much-needed progress to tackle the global challenge of AMR.”
“bioMérieux has a strong expertise in antimicrobial resistance. We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (antimicrobial stewardship),” said Alexandre Mérieux, bioMérieux Chairman and CEO. “Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results. This participation in Aurobac is perfectly aligned with bioMérieux’ full commitment to sustain antibiotic efficacy for future generations.”
Aurobac will work to shift the strategy related to antibiotic treatment regimens which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.
Funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each, the 40 million EUR joint venture, which has its headquarters in Lyon (France), combines the world leading expertise of Evotec, one of the most active research companies in infectious diseases, with bioMérieux’s market-leading expertise in infectious disease diagnostics and with Boehringer Ingelheim’s broad drug discovery and significant clinical development capabilities.
Three partners committed to combat AMR
Boehringer Ingelheim’s participation in Aurobac is part of a wider so-called pandemic preparedness initiative, which includes a 50 million EUR investment in the AMR action fund by Boehringer Ingelheim. Boehringer Ingelheim Venture Fund has committed to invest up to 12 million EUR in AMR infection companies.
bioMérieux has over 55 years of diagnostics expertise with more than 75 percent of its research and development budget focused on antimicrobial resistance. Moreover, 80 percent of its turnover is related to the fight against AMR through a complete diagnostic solution facilitating antibiotic therapy decision-making, including antibiotic initiation, optimization, and discontinuation.
Evotec has built a world-leading platform to tackle infectious diseases. With a more than 200-strong anti-infective discovery team, the company has proven experience on multiple agent classes. On top of the company’s own pre-competitive pandemic preparedness and rapid response technology platform (“PRROTECT”), Evotec leverages its infectious disease capabilities with many industry, academic and non-profit partners and is active in a variety of networks such as the AMR Accelerator that is part of the EU’s Innovative Medicines Initiative (“IMI”).
References
1
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext#seccestitle10
2
https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
Please click on the following link for ‘Notes to Editors’ and ‘References’:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005880/en/
Contact information
Boehringer Ingelheim
Corporate Affairs
Harro Ten Wolde
55216 Ingelheim
Phone: +49 151 61901069
Email: press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Options Selects atNorth Data Center for Private AI Solution18.11.2025 14:14:00 EET | Press release
Options Technology (Options), the leading provider of capital markets infrastructure, today announced a partnership with atNorth, the leading Nordic high-density colocation and built-to-suit datacenter provider, to host its expanded private AI solution, at atNorth’s ICE02 data center in Iceland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118956675/en/ Options Selects atNorth Data Center for Private AI Solution Options infrastructure expansion results from increasing demand from financial firms, such as hedge funds, investment banks, and proprietary trading firms, for high-density computing power, driven by the rapid adoption of AI for trading strategies, risk management, and data analytics. The business aims to address a gap in the market for private cloud infrastructure specifically tailored to the requirements of the financial services industry. Recognizing the need for a secure, sustainable, AI ready and cost-effec
Loyalty Upgraded: Hilton Honors Introduces Faster Path to Elite Status and Reveals New Premium Tier – Diamond Reserve18.11.2025 14:02:00 EET | Press release
Committed to rewarding loyalty at every stage of the travel journey, today Hilton (NYSE: HLT) announced exciting changes to its award-winning Hilton Honors loyalty program. Debuting this January, Hilton will introduce its most elite tier yet – Diamond Reserve – with new elevated benefits, including a Confirmable Upgrade Reward that can be instantly redeemed at the time of booking, guaranteed 4 p.m. late checkout, and exclusive customer service support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118002486/en/ (Photo: Hilton) Committed to rewarding loyalty at every stage of the travel journey, Hilton announced exciting changes to its award-winning Hilton Honors loyalty program. (Waldorf Astoria New York) What’s more, Hilton Honors Gold status will become the most valuable mid-tier status, with members still enjoying all the current benefits of Gold status, including space-available room upgrades and on-property Food & B
NIQ Launches New Brand Traction Score Designed to Reveal How Effectively FMCG Brands Convert Shelf Presence Into Real Consumer Purchases18.11.2025 13:45:00 EET | Press release
Coca-Cola has been recognised as the top FMCG brand in Western Europe for its success in driving conversions, according to NielsenIQ (NIQ)’s Brand Traction Score, a new metric that measures how effectively brands convert their shelf presence into actual consumer purchases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118769598/en/ NIQ Brand Traction Score The NIQ Brand Traction Score combines two of NIQ’s most powerful data sources: insights from its Consumer Panel, which tracks how frequently shoppers buy a brand, and its Retail Measurement data, which captures how widely and deeply that brand is distributed across stores. This strategy saw some of the top-performing brands grow by 40% due to expanding their presence, with more than 60% of their unit growth coming from households adding these brands to their category repertoire. There was also growth (18%) from existing buyers expanding their brand and category purchas
Barilla Opens Its New Innovation Center to Drive Food Innovation Worldwide18.11.2025 13:37:00 EET | Press release
How can we bring the excellence of Italian culinary tradition into the future? How can we transform everyday products into experiences that surprise the senses, create emotions, and accompany people in moments of pleasure, sharing, and discovery? The answer for Barilla Group is the Barilla Innovation & Technology Experience (BITE) in Parma, marking the company’s most significant investment in food innovation in recent years. With almost 14,000m², more than €20 million invested and an additional €2 million per year dedicated to equipment upgrades, BITE stands as a global hub designed to foster development across the Group’s portfolio. Pasta, sauces, and bakery become a territory of exploration here, where research and technology serve Barilla's passion for good food. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118376430/en/ Guido, Paolo and Luca Barilla. © Barilla Rooted in an approach of collaboration with leading inte
HP Becomes Sisvel Wi-Fi 6 Pool Licensee, Ending Disputes with Wilus, Huawei and Philips18.11.2025 11:58:00 EET | Press release
HP Inc and Sisvel have concluded an agreement for the Palo Alto-based global technology leader to become a licensee of the Sisvel Wi-Fi 6 patent pool. The deal follows a mediation process ordered by Judge Rodney Gilstrap, of the US District Court for the Eastern District of Texas, as part of patent infringement litigation brought against HP by Wilus Institute of Standards and Technology, a licensor in the pool. The agreement not only ends the Wilus suit, but also actions launched against HP by other Sisvel Wi-Fi 6 pool licensors, Huawei and Philips. HP now has one-stop access to approximately 2,000 patents (245 patent families) recognised to date, through the pool’s process of independent patent evaluations, as essential to the 802.11ax Wi-Fi 6 standard. Close to 40 entities license the patents in the Sisvel Wi-Fi 6 patent pool. In addition to HP Inc, these include other recent additions such as Cisco, Netgear and Acer. “We are grateful to HP for the constructive way in which they enga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom